-
Reflections on a Career in Pediatric Neuropathology, with a Note of Gratitude Ann. Review Paleopathol. Mech. Disease (IF 28.4) Pub Date : 2024-07-17 Hannah C. Kinney
I am honored to be asked by the journal to write this personal essay about my career in pediatric neuropathology—a life of immense satisfaction, meaning, and fulfillment. My motivation to enter this discipline is highlighted, as is my decision to perform brain research in the sudden infant death syndrome, the leading cause of postneonatal infant mortality in the United States today. I also touch upon
-
Impact of dietary n-6/n-3 fatty acid ratio of atherosclerosis risk: A review Prog. Lipid. Res. (IF 14.0) Pub Date : 2024-07-08 Minjie Cao, Fangwei Yang, David Julian McClements, Yiwen Guo, Ruijie Liu, Ming Chang, Wei Wei, Jun Jin, Xingguo Wang
Atherosclerosis is a causative factor associated with cardiovascular disease (CVD). Over the past few decades, extensive research has been carried out on the relationship between the n-6/n-3 fatty acid ratio of ingested lipids and the progression of atherosclerosis. However, there are still many uncertainties regarding the precise nature of this relationship, which has led to challenges in providing
-
Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma Drug Resist. Updat. (IF 15.8) Pub Date : 2024-07-06 Wei-Feng Hong, Feng Zhang, Nan Wang, Jun-Ming Bi, Ding-Wen Zhang, Lu-Sheng Wei, Zhen-Tao Song, Gordon B. Mills, Min-Min Chen, Xue-Xin Li, Shi-Suo Du, Min Yu
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, notably resistant to existing therapies. Current research indicates that PDAC patients deficient in homologous recombination (HR) benefit from platinum-based treatments and poly-ADP-ribose polymerase inhibitors (PARPi). However, the effectiveness of PARPi in HR-deficient (HRD) PDAC is suboptimal, and significant challenges remain in fully
-
A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis Drug Resist. Updat. (IF 15.8) Pub Date : 2024-07-03 Jinan Guo, Xiaoshi Ma, Dongcheng Liu, Fei Wang, Jinquan Xia, Bin Zhang, Pan Zhao, Fuhua Zhong, Lipeng Chen, Qiaoyun Long, Lu Jiang, Siyu Zhang, Naikai Liao, Jigang Wang, Weiqing Wu, Jichao Sun, Mou Huang, Zhiqiang Cheng, Guixiao Huang, Chang Zou
-
Circulating tumor cells with increasing aneuploidy predict inferior prognosis and therapeutic resistance in small cell lung cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-07-02 Zhongpeng Xie, Yanxia Wang, Tingfei Chen, Wei Fan, Lihong Wei, Bixia Liu, Xiaohua Situ, Qinru Zhan, Tongze Fu, Tian Tian, Shuhua Li, Qiong He, Jianwen Zhou, Huipin Wang, Juan Du, Hsian-Rong Tseng, Yiyan Lei, Ke-Jing Tang, Zunfu Ke
Treatment resistance commonly emerges in small cell lung cancer (SCLC), necessitating the development of novel and effective biomarkers to dynamically assess therapeutic efficacy. This study aims to evaluate the clinical utility of aneuploid circulating tumor cells (CTCs) for risk stratification and treatment response monitoring. A total of 126 SCLC patients (two cohorts) from two independent cancer
-
Leveraging altered lipid metabolism in treating B cell malignancies Prog. Lipid. Res. (IF 14.0) Pub Date : 2024-07-02 Jaewoong Lee, Arya Mani, Min-Jeong Shin, Ronald M. Krauss
B cell malignancies, comprising over 80 heterogeneous blood cancers, pose significant prognostic challenges due to intricate oncogenic signaling. Emerging evidence emphasizes the pivotal role of disrupted lipid metabolism in the development of these malignancies. Variations in lipid species, such as phospholipids, cholesterol, sphingolipids, and fatty acids, are widespread across B cell malignancies
-
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment Drug Resist. Updat. (IF 15.8) Pub Date : 2024-06-25 Antonino Glaviano, Seth A. Wander, Richard D. Baird, Kenneth C.-H. Yap, Hiu Yan Lam, Masakazu Toi, Daniela Carbone, Birgit Geoerger, Violeta Serra, Robert H. Jones, Joanne Ngeow, Eneda Toska, Justin Stebbing, Karen Crasta, Richard S. Finn, Patrizia Diana, Karla Vuina, Robertus A.M. de Bruin, Uttam Surana, Aditya Bardia, Alan Prem Kumar
Cell cycle dysregulation is a hallmark of cancer that promotes eccessive cell division. Cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key molecules in the G1-to-S phase cell cycle transition and are crucial for the onset, survival, and progression of breast cancer (BC). Small-molecule CDK4/CDK6 inhibitors (CDK4/6i) block phosphorylation of tumor suppressor Rb and thus restrain
-
Intercellular adhesion molecule-1 suppresses TMZ chemosensitivity in acquired TMZ-resistant gliomas by increasing assembly of ABCB1 on the membrane Drug Resist. Updat. (IF 15.8) Pub Date : 2024-06-24 Xin Zhang, Yingying Tan, Tao Li, Dashan Tan, Bin Fu, Mengdi Yang, Yaxin Chen, Mengran Cao, Chenyuan Xuan, Qianming Du, Rong Hu, Qing Wang
Despite aggressive treatment, the recurrence of glioma is an inevitable occurrence, leading to unsatisfactory clinical outcomes. A plausible explanation for this phenomenon is the phenotypic alterations that glioma cells undergo aggressive therapies, such as TMZ-therapy. However, the underlying mechanisms behind these changes are not well understood. The TMZ chemotherapy resistance model was employed
-
Cancer plasticity in therapy resistance: Mechanisms and novel strategies Drug Resist. Updat. (IF 15.8) Pub Date : 2024-06-22 Xing Niu, Wenjing Liu, Yinling Zhang, Jing Liu, Jianjun Zhang, Bo Li, Yue Qiu, Peng Zhao, Zhongmiao Wang, Zhe Wang
Therapy resistance poses a significant obstacle to effective cancer treatment. Recent insights into cell plasticity as a new paradigm for understanding resistance to treatment: as cancer progresses, cancer cells experience phenotypic and molecular alterations, corporately known as cell plasticity. These alterations are caused by microenvironment factors, stochastic genetic and epigenetic changes, and/or
-
Plant terpenoid biosynthetic network and its multiple layers of regulation Prog. Lipid. Res. (IF 14.0) Pub Date : 2024-06-19 Matthew E. Bergman, Ruy W.J. Kortbeek, Michael Gutensohn, Natalia Dudareva
Terpenoids constitute one of the largest and most chemically diverse classes of primary and secondary metabolites in nature with an exceptional breadth of functional roles in plants. Biosynthesis of all terpenoids begins with the universal five‑carbon building blocks, isopentenyl diphosphate (IPP) and its allylic isomer dimethylallyl diphosphate (DMAPP), which in plants are derived from two compartmentally
-
Surface chemistry engineered selenium nanoparticles as bactericidal and immuno-modulating dual-functional agents for combating methicillin-resistant Staphylococcus aureus Infection Drug Resist. Updat. (IF 15.8) Pub Date : 2024-06-15 Qingyue Bu, Dan Jiang, Yangyang Yu, Yunqing Deng, Tianfeng Chen, Ligeng Xu
Because of the extremely complexed microenvironment of drug-resistant bacterial infection, nanomaterials with both bactericidal and immuno-modulating activities are undoubtedly the ideal modality for overcoming drug resistance. Herein, we precisely engineered the surface chemistry of selenium nanoparticles (SeNPs) using neutral (polyvinylpyrrolidone-PVP), anionic (letinan-LET) and cationic (chitosan-CS)
-
LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein Drug Resist. Updat. (IF 15.8) Pub Date : 2024-06-14 Kai-Lin Chen, Sai-Wei Huang, Ji-Jin Yao, Shi-Wei He, Sha Gong, Xi-Rong Tan, Ye-Lin Liang, Jun-Yan Li, Sheng-Yan Huang, Ying-Qin Li, Yin Zhao, Han Qiao, Sha Xu, Shengbing Zang, Jun Ma, Na Liu
Gemcitabine (GEM) based induction chemotherapy is a standard treatment for locoregionally advanced nasopharyngeal carcinoma (NPC). However, approximately 15 % of patients are still resistant to GEM-containing chemotherapy, which leads to treatment failure. Nevertheless, the underlying mechanisms of GEM resistance remain poorly understood. Herein, based on a microarray analysis, we identified 221 dysregulated
-
Omega-3 world map: 2024 update Prog. Lipid. Res. (IF 14.0) Pub Date : 2024-06-13 Jan Philipp Schuchardt, Philine Beinhorn, Xue Feng Hu, Hing Man Chan, Kaitlin Roke, Aldo Bernasconi, Andreas Hahn, Aleix Sala-Vila, Ken D. Stark, William S. Harris
In 2016, the first worldwide n3 PUFA status map was published using the Omega-3 Index (O3I) as standard biomarker. The O3I is defined as the percentage of EPA + DHA in red blood cell (RBC) membrane FAs. The purpose of the present study was to update the 2016 map with new data. In order to be included, studies had to report O3I and/or blood EPA + DHA levels in metrics convertible into an estimated O3I
-
Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration Drug Resist. Updat. (IF 15.8) Pub Date : 2024-06-04 Ning Ji, Hui Li, Yixuan Zhang, Yuelin Li, Peiyu Wang, Xin Chen, Yi-Nan Liu, Jing-Quan Wang, Yuqi Yang, Zhe-Sheng Chen, Yueguo Li, Ran Wang, Dexin Kong
-
Targeting anoikis resistance as a strategy for cancer therapy Drug Resist. Updat. (IF 15.8) Pub Date : 2024-06-01 Yumin Wang, Sihang Cheng, Joshua S. Fleishman, Jichao Chen, Hailin Tang, Zhe-Sheng Chen, Wenkuan Chen, Mingchao Ding
Anoikis, known as matrix detachment-induced apoptosis or detachment-induced cell death, is crucial for tissue development and homeostasis. Cancer cells develop means to evade anoikis, e.g. anoikis resistance, thereby allowing for cells to survive under anchorage-independent conditions. Uncovering the mechanisms of anoikis resistance will provide details about cancer metastasis, and potential strategies
-
Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance Drug Resist. Updat. (IF 15.8) Pub Date : 2024-06-01 Zhijie Xu, Haiyan Zhou, Tongfei Li, Qiaoli Yi, Abhimanyu Thakur, Kui Zhang, Xuelei Ma, Jiang-Jiang Qin, Yuanliang Yan
Breakthroughs in actual clinical applications have begun through vaccine-based cancer immunotherapy, which uses the body's immune system, both humoral and cellular, to attack malignant cells and fight diseases. However, conventional vaccine approaches still face multiple challenges eliciting effective antigen-specific immune responses, resulting in immunotherapy resistance. In recent years, biomimetic
-
CircPDIA3/miR-449a/XBP1 feedback loop curbs pyroptosis by inhibiting palmitoylation of the GSDME-C domain to induce chemoresistance of colorectal cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-05-28 Jiatong Lin, Zejian Lyu, Huolun Feng, Huajie Xie, Jingwen Peng, Weifu Zhang, Jun Zheng, Jiabin Zheng, Zihao Pan, Yong Li
-
FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-05-27 Haotian Cao, Tianjun Lan, Shijia Kuang, Liansheng Wang, Jintao Li, Qunxin Li, Yanyan Li, Qiuping Xu, Qian Chen, Shuwei Ren, Chunhong Lan, Nengtai Ouyang, Jianwei Liao, Yongsheng Huang, Jinsong Li
Response to immunotherapy is the main challenge of head and neck squamous cancer (HNSCC) treatment. Previous studies have indicated that tumor mutational burden (TMB) is associated with prognosis, but it is not always a precise index. Hence, investigating specific genetic mutations and tumor microenvironment (TME) changes in TMB-high patients is essential for precision therapy of HNSCC. A total of
-
KLF12 interacts with TRIM27 to affect cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma by regulating L1CAM expression Drug Resist. Updat. (IF 15.8) Pub Date : 2024-05-27 Hao Zhang, Yujia Zheng, Zhen Wang, Lin Dong, Liyan Xue, Xiaolin Tian, Haiteng Deng, Qi Xue, Shugeng Gao, Yibo Gao, Chunxiang Li, Jie He
Krüppel-like factor 12 (KLF12) has been characterized as a transcriptional repressor, and previous studies have unveiled its roles in angiogenesis, neural tube defect, and natural killer (NK) cell proliferation. However, the contribution of KLF12 to cancer treatment remains undefined. Here, we show that KLF12 is downregulated in various cancer types, and KLF12 downregulation promotes cisplatin resistance
-
Oxylipin profiling for clinical research: Current status and future perspectives Prog. Lipid. Res. (IF 14.0) Pub Date : 2024-04-30 Karol Parchem, Sophia Letsiou, Toni Petan, Olga Oskolkova, Isabel Medina, Ondrej Kuda, Valerie B. O'Donnell, Anna Nicolaou, Maria Fedorova, Valery Bochkov, Cécile Gladine
Oxylipins are potent lipid mediators with increasing interest in clinical research. They are usually measured in systemic circulation and can provide a wealth of information regarding key biological processes such as inflammation, vascular tone, or blood coagulation. Although procedures still require harmonization to generate comparable oxylipin datasets, performing comprehensive profiling of circulating
-
Characterization of NMCR-3, NMCR-4 and NMCR-5, three novel non-mobile colistin resistance determinants: Implications for MCR-3, MCR-7, and MCR-5 progenitors, respectively Drug Resist. Updat. (IF 15.8) Pub Date : 2024-04-26 Yating Guo, Geng Zou, Anusak Kerdsin, Constance Schultsz, Can Hu, Weicheng Bei, Huanchun Chen, Jinquan Li, Yang Zhou
In this study, the progenitors of MCR-3, MCR-7 and MCR-5, namely NMCR-3, NMCR-4 and NMCR-5, were firstly discovered and indicating was a natural reservoir for MCR-3 and MCR-7. Furthermore, different evolutionary models for MCR-3, MCR-7 and MCR-5 were proposed.
-
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress Drug Resist. Updat. (IF 15.8) Pub Date : 2024-04-23 Sara Diaz-Diaz, Andrea Garcia-Montaner, Roberta Vanni, Marina Murillo-Torres, Esther Recacha, Marina R. Pulido, Maria Romero-Muñoz, Fernando Docobo-Pérez, Alvaro Pascual, Jose Manuel Rodriguez-Martinez
In recent years, new evidence has shown that the SOS response plays an important role in the response to antimicrobials, with involvement in the generation of clinical resistance. Here we evaluate the impact of heterogeneous expression of the SOS response in clinical isolates of on response to the fluoroquinolone, ciprofloxacin. analysis of whole genome sequencing data showed remarkable sequence conservation
-
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement Drug Resist. Updat. (IF 15.8) Pub Date : 2024-04-23 Mingxia Jiang, Qiao Li, Binghe Xu
Antibody-drug conjugates (ADCs) represent a novel and promising approach in targeted therapy, uniting the specificity of antibodies that recognize specific antigens with payloads, all connected by the stable linker. These conjugates combine the best targeted and cytotoxic therapies, offering the killing effect of precisely targeting specific antigens and the potent cell-killing power of small molecule
-
Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy Drug Resist. Updat. (IF 15.8) Pub Date : 2024-04-16 Qin Zhou, Xinyi Tu, Xiaonan Hou, Jia Yu, Fei Zhao, Jinzhou Huang, Jake Kloeber, Anna Olson, Ming Gao, Kuntian Luo, Shouhai Zhu, Zheming Wu, Yong Zhang, Chenyu Sun, Xiangyu Zeng, Kenneth J. Schoolmeester, John S. Weroha, Xiwen Hu, Yanxia Jiang, Liewei Wang, Robert W. Mutter, Zhenkun Lou
Enhanced DNA repair is an important mechanism of inherent and acquired resistance to DNA targeted therapies, including poly ADP ribose polymerase (PARP) inhibition. Spleen associated tyrosine kinase (Syk) is a non-receptor tyrosine kinase acknowledged for its regulatory roles in immune cell function, cell adhesion, and vascular development. This study presents evidence indicating that Syk expression
-
Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma Drug Resist. Updat. (IF 15.8) Pub Date : 2024-04-16 Hongxing Zhao, Yuhang Ling, Jie He, Jinling Dong, Qinliang Mo, Yao Wang, Ying Zhang, Hongbin Yu, Chengwu Tang
Hepatocellular carcinoma (HCC) is the most common digestive malignancyin the world, which is frequently diagnosed at late stage with a poor prognosis. For most patients with advanced HCC, the therapeutic options arelimiteddue to cancer occurrence of drug resistance. Hepatic cancer stem cells (CSCs) account for a small subset of tumor cells with the ability of self-renewal and differentiationin HCC
-
Expansion and transmission dynamics of high risk carbapenem-resistant Klebsiella pneumoniae subclones in China: An epidemiological, spatial, genomic analysis Drug Resist. Updat. (IF 15.8) Pub Date : 2024-03-29 Qi Wang, Ruobing Wang, Shuyi Wang, Anru Zhang, Qiaoyan Duan, Shijun Sun, Longyang Jin, Xiaojuan Wang, Yawei Zhang, Chunlei Wang, Haiquan Kang, Zhijie Zhang, Kang Liao, Yinghui Guo, Liang Jin, Zhiwu Liu, Chunxia Yang, Hui Wang, on behalf of the China Carbapenem-Resistant Enterobacterales (CRE) Network
Carbapenem-resistant (CRKP) is a global threat that varies by region. The global distribution, evolution, and clinical implications of the ST11 CRKP clone remain obscure. We conducted a multicenter molecular epidemiological survey using isolates obtained from 28 provinces and municipalities across China between 2011 and 2021. We integrated sequences from public databases and performed genetic epidemiology
-
Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies Drug Resist. Updat. (IF 15.8) Pub Date : 2024-03-26 Yuxian Huang, Yinjie Qin, Yingzhi He, Dezhi Qiu, Yeqin Zheng, Jiayue Wei, Lenghe Zhang, Dong‑Hua Yang, Yuhua Li
Molecular targeted drugs and chimeric antigen receptor (CAR) T cell therapy represent specific biological treatments that have significantly improved the efficacy of treating hematologic malignancies. However, they face challenges such as drug resistance and recurrence after treatment. Combining molecular targeted drugs and CAR-T cells could regulate immunity, improve tumor microenvironment (TME),
-
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome Drug Resist. Updat. (IF 15.8) Pub Date : 2024-03-19 Alberto Diaz-Jimenez, Maria Ramos, Barbara Helm, Sara Chocarro, Dario Lucas Frey, Shubham Agrawal, Kalman Somogyi, Ursula Klingmüller, Junyan Lu, Rocio Sotillo
Precision oncology has revolutionized the treatment of ALK-positive lung cancer with targeted therapies. However, an unmet clinical need still to address is the treatment of refractory tumors that contain drug-induced resistant mutations in the driver oncogene or exhibit resistance through the activation of diverse mechanisms. In this study, we established mouse tumor-derived cell models representing
-
Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics Drug Resist. Updat. (IF 15.8) Pub Date : 2024-03-19 Gang Che, Jie Yin, Wankun Wang, Yandong Luo, Yiran Chen, Xiongfei Yu, Haiyong Wang, Xiaosun Liu, Zhendong Chen, Xing Wang, Yu Chen, Xujin Wang, Kaicheng Tang, Jiao Tang, Wei Shao, Chao Wu, Jianpeng Sheng, Qing Li, Jian Liu
Gastric Cancer (GC) characteristically exhibits heterogeneous responses to treatment, particularly in relation to immuno plus chemo therapy, necessitating a precision medicine approach. This study is centered around delineating the cellular and molecular underpinnings of drug resistance in this context. We undertook a comprehensive multi-omics exploration of postoperative tissues from GC patients undergoing
-
Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models Drug Resist. Updat. (IF 15.8) Pub Date : 2024-03-13 Lu Yang, Arup Bhattacharya, Darrell Peterson, Yun Li, Xiaozhuo Liu, Elisabetta Marangoni, Valentina Robila, Yuesheng Zhang
Human epidermal growth factor receptor 2 (HER2) is an oncogenic receptor tyrosine kinase amplified in approximately 20% of breast cancer (BC). HER2-targeted therapies are the linchpin of treating HER2-positive BC. However, drug resistance is common, and the main resistance mechanism is unknown. We tested the hypothesis that drug resistance results mainly from inadequate or lack of inhibition of HER2
-
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC Drug Resist. Updat. (IF 15.8) Pub Date : 2024-03-12 Wenjie Huang, Xiaojun Hu, Xiang He, Dongyue Pan, Zhaorong Huang, Zhanfeng Gu, Guobing Huang, Ping Wang, Chunhui Cui, Yingfang Fan
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease. Chemotherapy based on gemcitabine (GEM) remains the first-line drug for patients with advanced PDAC. However, GEM resistance impairs its therapeutic effectiveness. Therefore, identifying effective therapeutic targets are urgently needed to overcome GEM resistance. The clinical significance of Tripartite Motif Containing 29 (TRIM29)
-
A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-03-06 Fang Wang, Xuejiao Yu, Jun Qian, Yumin Cao, Shunli Dong, Shenghua Zhan, Zhen Lu, Robert C. Bast Jr., Qingxia Song, Youguo Chen, Yi Zhang, Jinhua Zhou
Ovarian cancer patients with HR proficiency (HRP) have had limited benefits from PARP inhibitor treatment, highlighting the need for improved therapeutic strategies. In this study, we developed a novel SIK2 inhibitor, SIC-19, and investigated its potential to enhance the sensitivity and expand the clinical utility of PARP inhibitors in ovarian cancer. The SIK2 protein was modeled using a Molecular
-
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP Drug Resist. Updat. (IF 15.8) Pub Date : 2024-02-17 Carole Seguin-Devaux, Tomislav Mestrovic, Jacobus J. Arts, Didem Sen Karaman, Cristina Nativi, Dana Reichmann, Priyanka Sahariah, Younes Smani, Patricia Rijo, Mattia Mori, on behalf of the COST Action CA21145 EURESTOP
-
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy Drug Resist. Updat. (IF 15.8) Pub Date : 2024-02-13 Binglei Zhang, Jianxiang Shi, Xiaojing Shi, Xiaolu Xu, Le Gao, Song Li, Mengmeng Liu, Mengya Gao, Shuiling Jin, Jian Zhou, Dandan Fan, Fang Wang, Zhenyu Ji, Zhilei Bian, Yongping Song, Wenzhi Tian, Yichao Zheng, Linping Xu, Wei Li
The treatment for trastuzumab-resistant breast cancer (BC) remains a challenge in clinical settings. It was known that CD47 is preferentially upregulated in HER2 BC cells, which is correlated with drug resistance to trastuzumab. Here, we developed a novel anti-CD47/HER2 bispecific antibody (BsAb) against trastuzumab-resistant BC, named IMM2902. IMM2902 demonstrated high binding affinity, blocking activity
-
AI in infectious diseases: The role of datasets Drug Resist. Updat. (IF 15.8) Pub Date : 2024-02-10 C, e, s, a, r, , d, e, , l, a, , F, u, e, n, t, e, -, N, u, n, e, z
-
Tumor-acquired somatic mutation affects conformation to abolish ABCG2-mediated drug resistance Drug Resist. Updat. (IF 15.8) Pub Date : 2024-02-06 Tomoka Gose, Ali Rasouli, Sepehr Dehghani-Ghahnaviyeh, Po-Chao Wen, Yao Wang, John Lynch, Yu Fukuda, Talha Shafi, Robert C. Ford, Emad Tajkhorshid, John D. Schuetz
ABCG2 is an important ATP-binding cassette transporter impacting the absorption and distribution of over 200 chemical toxins and drugs. ABCG2 also reduces the cellular accumulation of diverse chemotherapeutic agents. Acquired somatic mutations in the phylogenetically conserved amino acids of ABCG2 might provide unique insights into its molecular mechanisms of transport. Here, we identify a tumor-derived
-
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C Drug Resist. Updat. (IF 15.8) Pub Date : 2024-02-06 Zi-Ning Lei, Najah Albadari, Qiu-Xu Teng, Hadiar Rahman, Jing-Quan Wang, Zhongzhi Wu, Dejian Ma, Suresh V. Ambudkar, John N.D. Wurpel, Yihang Pan, Wei Li, Zhe-Sheng Chen
To investigate the collateral sensitivity (CS) of ABCB1-positive multidrug resistant (MDR) colorectal cancer cells to the survivin inhibitor MX106–4C and the mechanism. Biochemical assays (MTT, ATPase, drug accumulation/efflux, Western blot, RT-qPCR, immunofluorescence, flow cytometry) and bioinformatic analyses (mRNA-sequencing, reversed-phase protein array) were performed to investigate the hypersensitivity
-
Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness Drug Resist. Updat. (IF 15.8) Pub Date : 2024-02-04 Qingxiang Lin, Andrea Serratore, Jin Niu, Shichen Shen, Tista Roy Chaudhuri, Wen Wee Ma, Jun Qu, Eugene S. Kandel, Robert M. Straubinger
Pancreatic ductal adenocarcinoma (PDAC) is often intrinsically-resistant to standard-of-care chemotherapies such as gemcitabine. Acquired gemcitabine resistance (GemR) can arise from treatment of initially-sensitive tumors, and chemotherapy can increase tumor aggressiveness. We investigated the molecular mechanisms of chemoresistance and chemotherapy-driven tumor aggressiveness, which are understood
-
Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-02-01 Xueqi Ou, Yeru Tan, Jindong Xie, Jingping Yuan, Xinpei Deng, Ruonan Shao, Cailu Song, Xi Cao, Xiaoming Xie, Rongfang He, Yuehua Li, Hailin Tang
This study aims to explore the function and mechanism of G Protein-coupled receptor class C group 5 member A (GPRC5A) in docetaxel-resistance and liver metastasis of breast cancer. Single-cell RNA transcriptomic analysis and bioinformatic analysis are used to screen relevant genes in breast cancer metastatic hepatic specimens. MeRIP, dual-luciferase analysis and bioinformation were used to detect m6A
-
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-29 Da-Qian Chen, Yuhao Xie, Lu-Qi Cao, Joshua S. Fleishman, Yang Chen, Tiesong Wu, Dong-Hua Yang
Multidrug resistance protein 7 (MRP7), also known as ATP-binding cassette (ABC) transporter subfamily C10 (ABCC10), is an ABC transporter that was first identified in 2001. ABCC10/MRP7 is a 171 kDa protein located on the basolateral membrane of cells. ABCC10/MRP7 consists of three transmembrane domains and two nucleotide binding domains. It mediates multidrug resistance of tumor cells to a variety
-
Phage-mediated colistin resistance in Acinetobacter baumannii Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-28 Massimiliano Lucidi, Francesco Imperi, Irene Artuso, Giulia Capecchi, Cinzia Spagnoli, Daniela Visaggio, Giordano Rampioni, Livia Leoni, Paolo Visca
Antimicrobial resistance is a global threat to human health, and is a paradigmatic example of how rapidly bacteria become resistant to clinically relevant antimicrobials. The emergence of multidrug-resistant . strains has forced the revival of colistin as a last-resort drug, suddenly leading to the emergence of colistin resistance. We investigated the genetic and molecular basis of colistin resistance
-
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-26 Shaoqing Du, Xueping Hu, Luis Menéndez-Arias, Peng Zhan, Xinyong Liu
Viral infections have a major impact in human health. Ongoing viral transmission and escalating selective pressure have the potential to favor the emergence of vaccine- and antiviral drug-resistant viruses. Target-based approaches for the design of antiviral drugs can play a pivotal role in combating drug-resistant challenges. Drug design computational tools facilitate the discovery of novel drugs
-
Lipid oxidation in emulsions: New insights from the past two decades Prog. Lipid. Res. (IF 14.0) Pub Date : 2024-01-26 Marie Hennebelle, Pierre Villeneuve, Erwann Durand, Jérôme Lecomte, John van Duynhoven, Anne Meynier, Betül Yesiltas, Charlotte Jacobsen, Claire Berton-Carabin
Lipid oxidation constitutes the main source of degradation of lipid-rich foods, including food emulsions. The complexity of the reactions at play combined with the increased demand from consumers for less processed and more natural foods result in additional challenges in controlling this phenomenon. This review provides an overview of the insights acquired over the past two decades on the understanding
-
Acetaminophen Hepatotoxicity: Paradigm for Understanding Mechanisms of Drug-Induced Liver Injury Ann. Review Paleopathol. Mech. Disease (IF 28.4) Pub Date : 2024-01-24 Hartmut Jaeschke, Anup Ramachandran
Acetaminophen (APAP) overdose is the clinically most relevant drug hepatotoxicity in western countries, and, because of translational relevance of animal models, APAP is mechanistically the most studied drug. This review covers intracellular signaling events starting with drug metabolism and the central role of mitochondrial dysfunction involving oxidant stress and peroxynitrite. Mitochondria-derived
-
Chance and Opportunity: A Personal Story Ann. Review Paleopathol. Mech. Disease (IF 28.4) Pub Date : 2024-01-24 Abul K. Abbas
This article summarizes my personal life story, from early education in India to research, teaching, and other activities in Boston and San Francisco. I have tried to illustrate how unplanned events shape one's path, and why the willingness to go with the flow is among one's most valuable attributes.
-
Pediatric Cholestatic Diseases: Common and Unique Pathogenic Mechanisms Ann. Review Paleopathol. Mech. Disease (IF 28.4) Pub Date : 2024-01-24 Harry Sutton, Saul J. Karpen, Binita M. Kamath
Cholestasis is the predominate feature of many pediatric hepatobiliary diseases. The physiologic flow of bile requires multiple complex processes working in concert. Bile acid (BA) synthesis and excretion, the formation and flow of bile, and the enterohepatic reuptake of BAs all function to maintain the circulation of BAs, a key molecule in lipid digestion, metabolic and cellular signaling, and, as
-
Neutrophils in Physiology and Pathology Ann. Review Paleopathol. Mech. Disease (IF 28.4) Pub Date : 2024-01-24 Alejandra Aroca-Crevillén, Tommaso Vicanolo, Samuel Ovadia, Andrés Hidalgo
Infections, cardiovascular disease, and cancer are major causes of disease and death worldwide. Neutrophils are inescapably associated with each of these health concerns, by either protecting from, instigating, or aggravating their impact on the host. However, each of these disorders has a very different etiology, and understanding how neutrophils contribute to each of them requires understanding the
-
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-20 Kenneth K.W. To, Zoufang Huang, Hang Zhang, Charles R. Ashby Jr., Liwu Fu
Multidrug resistance (MDR) is one of the primary factors that produces treatment failure in patients receiving cancer chemotherapy. MDR is a complex multifactorial phenomenon, characterized by a decrease or abrogation of the efficacy of a wide spectrum of anticancer drugs that are structurally and mechanistically distinct. The overexpression of the ATP-binding cassette (ABC) transporters, notably ABCG2
-
Polyphenol nanocomplex modulates lactate metabolic reprogramming and elicits immune responses to enhance cancer therapeutic effect Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-20 Zhan Zhang, Xinnan Li, Weiqiang Liu, Guanglei Chen, Jinchi Liu, Qingtian Ma, Pengjie Hou, Lu Liang, Caigang Liu
Cancer lactate metabolic reprogramming induces an elevated level of extracellular lactate and H, leading to an acidic immunosuppressive tumor microenvironment (TEM). High lactic acid level may affect the metabolic programs of various cells that comprise an antitumor immune response, therefore, restricting immune-mediated tumor destruction, and leading to therapeutic resistance and unsatisfactory prognosis
-
MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-19 Jiaqi Liang, Guoshu Bi, Yiwei Huang, Guangyin Zhao, Qihai Sui, Huan Zhang, Yunyi Bian, Jiacheng Yin, Qun Wang, Zhencong Chen, Cheng Zhan
Lung cancer is the leading cause of cancer mortality and lung adenocarcinoma (LUAD) accounts for more than half of all lung cancer cases. Tumor elimination is mostly hindered by drug resistance and the mechanisms remain to be explored in LUAD. CRISPR screens in cell and murine models and single-cell RNA sequencing were conducted, which identified MAF bZIP transcription factor F (MAFF) as a critical
-
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-19 Jianhua Cheng, Weiyan Xie, Yiyuan Chen, Yingxuan Sun, Lei Gong, Hongyun Wang, Chuzhong Li, Yazhuo Zhang
The treatment of dopamine agonists (DA) resistant prolactinomas remains a formidable challenge, as the mechanism of resistance is still unclear, and there are currently no viable alternative drug therapies available. This study seeks to investigate the mechanism of DA resistance in prolactinomas and identify new potentially effective drugs. To explore the mechanism of DA resistance in prolactinomas
-
Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-19 Fei Li, Henghui Zhang, Yuan Huang, Dongqing Li, Zaosong Zheng, Kunfeng Xie, Chun Cao, Qiong Wang, Xinlei Zhao, Zehai Huang, Shijun Chen, Haiyong Chen, Qin Fan, Fan Deng, Lina Hou, Xiaolin Deng, Wanlong Tan
Patients with bladder cancer (BCa) frequently acquires resistance to platinum-based chemotherapy, particularly cisplatin. This study centered on the mechanism of cisplatin resistance in BCa and highlighted the pivotal role of lactylation in driving this phenomenon. Utilizing single-cell RNA sequencing, we delineated the single-cell landscape of Bca, pinpointing a distinctive subset of BCa cells that
-
Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-18 Jie Chen, Di Zhao, Lingyuan Zhang, Jing Zhang, Yuanfan Xiao, Qingnan Wu, Yan Wang, Qimin Zhan
Tumor-associated macrophages (TAMs) are often associated with chemoresistance and resultant poor clinical outcome in solid tumors. Here, we demonstrated that TAMs-released chemokine-C-C motif chemokine 22 (CCL22) in esophageal squamous cell carcinoma (ESCC) stroma was tightly correlated with the chemoresistance of ESCC patients. TAMs-secreted CCL22 was able to block the growth inhibitory and apoptosis-promoting
-
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-17 Yuna Kim, Kwan-Young Jung, Yun Hak Kim, Pan Xu, Baeki E. Kang, Yunju Jo, Navin Pandit, Jeongho Kwon, Karim Gariani, Joanna Gariani, Junguee Lee, Jef Verbeek, Seungyoon Nam, Sung-Jin Bae, Ki-Tae Ha, Hyon-Seung Yi, Minho Shong, Kyun-Hwan Kim, Doyoun Kim, Hee Jung Jung, Chang-Woo Lee, Kwang Rok Kim, Kristina Schoonjans, Johan Auwerx, Dongryeol Ryu
-
-
Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-10 Shi-Hui Hao, Xiao-Dan Ma, Li Xu, Jing-Dun Xie, Zi-Hao Feng, Jie-Wei Chen, Ri-Xin Chen, Feng-Wei Wang, Yu-Hao Tang, Dan Xie, Mu-Yan Cai
-
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-09 Hailin Zou, Juan Luo, Yibo Guo, Liang Deng, Leli Zeng, Yihang Pan, Peng Li
Trastuzumab resistance in HER2+ breast cancer (BC) is the major reason leading to poor prognosis of BC patients. Oncogenic gene overexpression or aberrant activation of tyrosine kinase SRC is identified to be the key modulator of trastuzumab response. However, the detailed regulatory mechanisms underlying SRC activation-associated trastuzumab resistance remain poorly understood. In the present study
-
NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1 Drug Resist. Updat. (IF 15.8) Pub Date : 2024-01-09 Zhiheng Zhang, Bojiao Song, Haowei Wei, Yang Liu, Wenjie Zhang, Yuhong Yang, Beicheng Sun
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that is resistant to immune checkpoint blockade (ICB) therapies. Emerging evidence suggests that NDRG1 may be an important target for the development of new therapies for PDAC. Herein, we investigated the novel roles of NDRG1 and Combretastatin A-4 (CA-4) in the treatment of PDAC ICB resistance. Enrichment of MHC class I was detected by RNA
-
Mitochondrial phospholipid transport: Role of contact sites and lipid transport proteins Prog. Lipid. Res. (IF 14.0) Pub Date : 2024-01-07 Vijay Aditya Mavuduru, Lavanya Vadupu, Krishna Kanta Ghosh, Sabyasachi Chakrabortty, Balázs Gulyás, Parasuraman Padmanabhan, Writoban Basu Ball
One of the major constituents of mitochondrial membranes is the phospholipids, which play a key role in maintaining the structure and the functions of the mitochondria. However, mitochondria do not synthesize most of the phospholipids , necessitating the presence of phospholipid import pathways. Even for the phospholipids, which are synthesized within the inner mitochondrial membrane (IMM), the phospholipid
-